Pharm'Up

An E-platform for Learners

Biocon Biologics Gains Health Canada Approval for Yesintek™ (Ustekinumab) Biosimilar to Treat Psoriasis and Autoimmune Conditions

Biocon Biologics Gains Health Canada Approval for Yesintek™ (Ustekinumab) Biosimilar to Treat Psoriasis and Autoimmune Conditions

Pharm'Up

Biocon Biologics Ltd (BBL), a global biosimilars company, announced that it received a Notice of Compliance (NOC)...

Novartis to Acquire RNA Therapeutics Innovator Avidity Biosciences for $12 Billion to Bolster Neuroscience and Muscle Disease Pipeline

Novartis to Acquire RNA Therapeutics Innovator Avidity Biosciences for $12 Billion to Bolster Neuroscience and Muscle Disease Pipeline

Pharm'Up

Novartis announced a definitive agreement to acquire Avidity Biosciences, Inc. (Nasdaq: RNA), a San Diego-based biopharmaceutical company...

USFDA Approves GSK’s Blenrep for Relapsed/Refractory Multiple Myeloma, Showing Superiority Over Daratumumab-based Regimen

USFDA Approves GSK’s Blenrep for Relapsed/Refractory Multiple Myeloma, Showing Superiority Over Daratumumab-based Regimen

Pharm'Up

GSK plc has announced that the US Food and Drug Administration (FDA) has granted approval for Blenrep...

Dr. Reddy’s to Launch Affordable Generic Version of Wegovy (Semaglutide) in 87 Countries

Dr. Reddy’s to Launch Affordable Generic Version of Wegovy (Semaglutide) in 87 Countries

Pharm'Up

Dr. Reddy’s Laboratories Ltd., a leading Indian pharmaceutical firm, is preparing a significant global market entry with...

Mazdutide, a Dual GLP-1/GCG Agonist, Demonstrates Superiority Over Semaglutide in Glycemic Control and Weight Loss for Type 2 Diabetes Patients

Mazdutide, a Dual GLP-1/GCG Agonist, Demonstrates Superiority Over Semaglutide in Glycemic Control and Weight Loss for Type 2 Diabetes Patients

Pharm'Up

Innovent Biologics announced that its fourth Phase 3 clinical trial, DREAMS-3, evaluating the novel drug mazdutide in...

Lupin Expands U.S. Footprint with New Corporate Headquarters in New Jersey

Lupin Expands U.S. Footprint with New Corporate Headquarters in New Jersey

Pharm'Up

Global pharmaceutical leader, Lupin Limited (Lupin), officially marked a major milestone in its United States operations with...

Merck’s Combo Therapy KEYTRUDA + WELIREG Hits Primary Endpoint in Kidney Cancer Adjuvant Trial (LITESPARK-022)

Merck’s Combo Therapy KEYTRUDA + WELIREG Hits Primary Endpoint in Kidney Cancer Adjuvant Trial (LITESPARK-022)

Pharm'Up

Merck (known as MSD outside North America) has announced positive top-line results from its Phase 3 LITESPARK-022...

Teva Settles QVAR Antitrust Case for $35 Million and Agrees to Withdraw Patents, Resolving Generic Delay Claims

Teva Settles QVAR Antitrust Case for $35 Million and Agrees to Withdraw Patents, Resolving Generic Delay Claims

Pharm'Up

Teva Pharmaceuticals USA, Inc., has agreed to a $35 million settlement to resolve a class action lawsuit...

Novel Antibody-Drug Conjugate Patritumab Deruxtecan Shows Strong Efficacy Against Active Brain Metastases

Novel Antibody-Drug Conjugate Patritumab Deruxtecan Shows Strong Efficacy Against Active Brain Metastases

Pharm'Up

An international Phase 2 clinical study, TUXEDO-3, led by the Medical University of Vienna, has yielded highly...

Researchers Uncover ‘Perineural Pathway’ Allowing HIV to Escape the Brain and Reseed the Body Despite Antiretroviral Therapy

Researchers Uncover ‘Perineural Pathway’ Allowing HIV to Escape the Brain and Reseed the Body Despite Antiretroviral Therapy

Pharm'Up

New research published in The American Journal of Pathology by investigators from Boston College and the Tulane...